Real-world assessment of treatment with extended-release topiramate (Trokendi XR ® ) and comparison with previous immediate-release topiramate treatment | Zendy

Welton O’Neal | Zendy; Elizabeth E. Hur | Zendy; Tesfaye Liranso | Zendy; Barry Patel | Zendy

Open Access

Real-world assessment of treatment with extended-release topiramate (Trokendi XR ^® ) and comparison with previous immediate-release topiramate treatment

Author(s) -

Welton O’Neal,

Elizabeth E. Hur,

Tesfaye Liranso,

Barry Patel

Publication year - 2018

Publication title -

journal of comparative effectiveness research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.567

H-Index - 23

eISSN - 2042-6313

pISSN - 2042-6305

DOI - 10.2217/cer-2018-0074

Subject(s) - topiramate , medicine , extended release , pharmacology , psychiatry , epilepsy

Aim: Examine clinical profile of extended-release topiramate (Trokendi XR ® ) and compare treatment-emergent adverse events (TEAEs) associated with Trokendi XR versus previous immediate-release topiramate (TPM-IR) treatment. Patients & methods: Pilot retrospective study analyzing data extracted from medical charts of patients ≥6 years of age prescribed Trokendi XR. Results: Trokendi XR was the most commonly used to prevent migraine. The most common TEAEs recorded during topiramate treatment were cognitive symptoms (word-finding difficulty, attention/concentration difficulty, slowed thinking), paresthesia, gastrointestinal problems and decreased appetite/weight loss. TEAE incidence was significantly (p < 0.001) lower during Trokendi XR versus previous TPM-IR treatment. Conclusion: Trokendi XR use and outcomes in clinical practice were consistent with established profile of topiramate. Results supported the potential for better tolerability of Trokendi XR versus TPM-IR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research